VYNE Therapeutics Inc. - ROE
VYNE
Price:
$0.6354
Market Cap:
$10.59M
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a r...[Read more]
Industry
Biotechnology
IPO Date
2018-01-25
Stock Exchange
NASDAQ
Ticker
VYNE
PE Ratio
[-1.25]
ROE
[-69.57%]
Current Ratio
[20.86]
Dividend Yield
[0%]
Enterprise Value
[-14042123.00]
Dividend History
The ROE as of June 2026 (TTM) for VYNE Therapeutics Inc. (VYNE) is -69.57%
According to VYNE Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -69.57%. This represents a change of 300.62% compared to the average of -17.37% of the last 4 quarters.
VYNE Therapeutics Inc. (VYNE) Historical ROE (quarterly & annually)
How has VYNE ROE performed in the past?
The mean historical ROE of VYNE Therapeutics Inc. over the last ten years is -115.43%. The current -69.57% ROE has changed -39.73% with respect to the historical average. Over the past ten years (40 quarters), VYNE's ROE was at its highest in in the September 2017 quarter at 17.04%. The ROE was at its lowest in in the June 2020 quarter at -234.09%.
Average
-115.43%
Median
-75.43%
Minimum
-681.64%
Maximum
50.98%
VYNE Therapeutics Inc. (VYNE) ROE by Quarter and Year
Discovering the peaks and valleys of VYNE Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 562.72%
Maximum Annual ROE = 50.98%
Minimum Annual Increase = -177.40%
Minimum Annual ROE = -681.64%
| Year | ROE | Change |
|---|---|---|
| 2025 | -95.38% | 24.72% |
| 2024 | -76.48% | 138.51% |
| 2023 | -32.06% | -56.90% |
| 2022 | -74.39% | -50.66% |
| 2021 | -150.77% | -77.88% |
| 2020 | -681.64% | 562.72% |
| 2019 | -102.86% | 160.67% |
| 2018 | -39.46% | -177.40% |
| 2017 | 50.98% | 6.69% |
| 2016 | 47.78% | 65.43% |
VYNE Therapeutics Inc. (VYNE) Average ROE
How has VYNE ROE performed in the past?
The current ROE of VYNE Therapeutics Inc. (VYNE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-67.97%
5-year avg
-85.82%
10-year avg
-115.43%
VYNE Therapeutics Inc. (VYNE) ROE vs. Peers
How is VYNE’s ROE compared to its peers?
VYNE Therapeutics Inc.’s ROE is less than AIM ImmunoTech Inc. (261.84%), greater than KALA BIO, Inc. (-1335.64%), greater than Pasithea Therapeutics Corp. (-57.44%), greater than Soligenix, Inc. (-246.04%), greater than Alaunos Therapeutics, Inc. (-165.94%), less than Brainstorm Cell Therapeutics Inc. (109.21%), greater than Quoin Pharmaceuticals, Ltd. (-292.33%), greater than Ensysce Biosciences, Inc. (-631.47%), greater than XTL Biopharmaceuticals Ltd. (-26.83%), greater than Matinas BioPharma Holdings, Inc. (-204.27%),
| Company | ROE | Market cap |
|---|---|---|
| 261.84% | $1.29M | |
| -1335.64% | $79.17M | |
| -57.44% | $3.72M | |
| -246.04% | $4.12M | |
| -165.94% | $5.25M | |
| 109.21% | $9.49M | |
| -292.33% | $9.34M | |
| -631.47% | $2.52M | |
| -26.83% | $6.01M | |
| -204.27% | $3.35M |
Build a custom stock screener for VYNE Therapeutics Inc. (VYNE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like VYNE Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
VYNE Therapeutics Inc. (VYNE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like VYNE Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is VYNE Therapeutics Inc.'s ROE?
How is the ROE calculated for VYNE Therapeutics Inc. (VYNE)?
What is the highest ROE for VYNE Therapeutics Inc. (VYNE)?
What is the 3-year average ROE for VYNE Therapeutics Inc. (VYNE)?
What is the 5-year average ROE for VYNE Therapeutics Inc. (VYNE)?
How does the current ROE for VYNE Therapeutics Inc. (VYNE) compare to its historical average?